drugset
drugset / Trial / NCT04610580

Bioavailability Study of 2 Oral Formulations of ALXN1840

NCT04610580 ↗

Phase 1 Completed 48 enrolled Alexion Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The study will assess the relative bioavailability of 2 different formulations of ALXN1840 in healthy participants.

Timeline

Start
2021-01-31
Primary completion
2021-03-24
Completion
2021-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject TIOMOLIBDATE CHOLINE Small molecule — Oral

Indications

No indication recorded.